Our Firm is currently investigating allegations that Lipitor has caused some patients to develop new-onset Type 2 diabetes. As such, we are monitoring the federal litigation underway in South Carolina with great interest.
New York, New York (PRWEB) November 24, 2014
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege the statin drug may increase the risk that a patient will develop Type 2 diabetes continue to move forward in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. On November 13th, the Court issued a new Case Management Order that addresses several Motions put forth by the parties involved in the proceeding. Among other things, the Order denies Pfizer, Inc.’s Motion to Quash the Plaintiffs’ deposition notice on a former official with the company, finding that the Plaintiffs have put forth evidence indicating that the individual in question may have personal information relevant to their cases. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is currently investigating allegations that Lipitor has caused some patients to develop new-onset Type 2 diabetes. As such, we are monitoring the federal litigation underway in South Carolina with great interest,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Court documents indicate that more than 1,400 Lipitor lawsuits have been filed in the District of South Carolina, all which accuse Pfizer Inc. of concealing information about the drug’s association with diabetes in order to protect sales of the medication. Plaintiffs further allege that information pertaining to this potential complication that was added Lipitor label in 2012 still does not provide patients with adequate warning about this risk.
According to court documents, the litigation surrounding Lipitor and diabetes has been mounting since February 2012, when the U.S. Food & Drug Administration (FDA) announced that the labels for it and other statins would be updated to include new information about their potential association with Type 2 diabetes. The announcement followed the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *
Individuals who developed Type 2 diabetes allegedly associated with their use of Lipitor may be entitled to take legal action against Pfizer, Inc. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com